Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Tarih
2017
Yazar
Karadogan, I.
Sonmez, M.
Gulbas, Z.
Tekgunduz, E.
Kaya, A. H.
Ozbalak, M.
Kaynar, L.
Yildirim, R.
Arat, M.
Tastemir, N.
Bekoz, H.
Karadurmus, N.
Paydas, S.
Turker, A.
Toptas, T.
Tuglular, T. Firatli
Ferhanoglu, B.
Demirkol, O.
Demirkurek, H. C.
Yilmaz, M.
Toprak, S. K.
Koseoglu, F. D.
Demirkaya, M.
Barista, I.
Hacioglu, S. Kabukcu
Dogu, M. H.
Ozcan, M.
Yuksel, M. Kurt
Turgut, M.
Abali, H.
Ozkocaman, V.
Tanrikulu, F. Pepedil
Üst veri
Tüm öğe kaydını göster
Özet
Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile.
Bağlantı
http://hdl.handle.net/20.500.12627/30315
https://doi.org/10.1093/annonc/mdx341
Koleksiyonlar